Pharma News

The Union Cabinet, chaired by the Hon'ble Prime Minister Shri Narendra Modi, today approved the National Medical Devices Policy, 2023.

Arterial stiffness may be a novel risk factor for metabolic syndrome in teens, a paper published in the American Journal of Physiology-Heart and Circulatory Physiology concludes. The study was conducted in collaboration between the University of Bristol in the UK, the University of Exeter in the UK, and the University of Eastern Finland.

Research molecule of Novartis, Iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naive paroxysmal nocturnal hemoglobinuria patients, as per recent trials.

The trial met its primary endpoint and demonstrated clinically meaningful benefits across secondary endpoints. These data were presented at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

Amphastar is the ideal company to continue Lilly's mission to help more people benefit from BAQSIMI

Sun Pharma and includes its subsidiaries and/or associate companies) announced that one of its wholly-owned subsidiaries has launched a novel ophthalmology treatment, CEQUA®, in India for patients who have Dry Eye Disease (DED) with inflammation, a commonly occurring condition. CEQUA® is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL®)* technology.

Drinking cranberry juice has long been a mythical prevention strategy for women who develop a urinary tract infection – and new medical evidence shows consuming cranberry products is an effective way to prevent a UTI before it gets started.

Researchers at NYU Grossman School of Medicine and Janssen Biotech Inc. have shown in early tests that a bioengineered drug candidate can counter infection with Staphylococcus aureus—a bacterial species widely resistant to antibiotics and a major cause of death in hospitalized patients.

Cancer drugs that stimulate the body’s immune system to attack tumors are a promising way to treat many types of cancer. However, some of these drugs produce too much systemic inflammation when delivered intravenously, making them harmful to use in patients.

Scientists in Melbourne have designed a new type of oral capsule that could mean pain-free delivery of insulin and other protein drugs. Co-lead researcher Professor Charlotte Conn, a biophysical chemist from RMIT University, said protein drugs had proven challenging to deliver orally as the drugs degrade very quickly in the stomach – until now.